Literature DB >> 18783316

Emergence and persistence of CXCR4-tropic HIV-1 in a population of men from the multicenter AIDS cohort study.

James C Shepherd1, Lisa P Jacobson, Wei Qiao, Beth D Jamieson, John P Phair, Paolo Piazza, Thomas C Quinn, Joseph B Margolick.   

Abstract

We examined the emergence of CXCR4 (i.e., X4) tropism in 67 male human immunodeficiency virus type 1 (HIV-1) seroconverters from the Multicenter AIDS Cohort Study (MACS) who were selected to reflect the full spectrum of rates of HIV-1 disease progression. A mean of 10 serial samples per donor were evaluated by a laboratory-validated, commercially available assay to determine phenotypic coreceptor use. A total of 52% of men had dual- or mixed-tropic HIV-1 detected at 1 or more of the time points tested. Use of X4 by HIV-1 was detected more frequently among men who developed AIDS (defined as a CD4(+) T cell count of <200 cells/muL and/or an AIDS-defining illness) < or =11 years after seroconversion than among those who did not (P = .005), as well as among men who exhibited a total T cell count decline (i.e., a CD3(+) inflection point), compared with those who did not (P = .03). For men in whom both X4 virus and an inflection point were detected, emergence of X4 virus preceded the inflection point by a median of 0.83 years. The median CD4(+) T cell count at first detection of X4 viruses before the onset of AIDS was 475 cells/microL. We conclude that HIV-1 variants that used X4 frequently emerged at high CD4(+) T cell counts and may contribute to the decrease in T cell numbers during late HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18783316      PMCID: PMC2753263          DOI: 10.1086/591623

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  29 in total

1.  Causal relationships between HIV-1 coreceptor utilization, tropism, and pathogenesis in human thymus.

Authors:  R D Berkowitz; S Alexander; J M McCune
Journal:  AIDS Res Hum Retroviruses       Date:  2000-07-20       Impact factor: 2.205

2.  Entry inhibitors: a primer on the class and on its most promising agents.

Authors:  James C Shepherd; Thomas C Quinn
Journal:  Hopkins HIV Rep       Date:  2004-07

3.  Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy.

Authors:  Zabrina L Brumme; Winnie W Y Dong; Benita Yip; Brian Wynhoven; Noah G Hoffman; Ronald Swanstrom; Mark A Jensen; James I Mullins; Robert S Hogg; Julio S G Montaner; P Richard Harrigan
Journal:  AIDS       Date:  2004-03-05       Impact factor: 4.177

4.  Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection.

Authors:  R Shankarappa; J B Margolick; S J Gange; A G Rodrigo; D Upchurch; H Farzadegan; P Gupta; C R Rinaldo; G H Learn; X He; X L Huang; J I Mullins
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

5.  Strong association between failure of T cell homeostasis and the syncytium-inducing phenotype among HIV-1-infected men in the Amsterdam Cohort Study.

Authors:  J J Maas; S J Gange; H Schuitemaker; R A Coutinho; R van Leeuwen; J B Margolick
Journal:  AIDS       Date:  2000-06-16       Impact factor: 4.177

6.  Cytopathicity of human immunodeficiency virus type 1 primary isolates depends on coreceptor usage and not patient disease status.

Authors:  J F Kreisberg; D Kwa; B Schramm; V Trautner; R Connor; H Schuitemaker; J I Mullins; A B van't Wout; M A Goldsmith
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

7.  Impact of antiretroviral treatment on the tropism of HIV-1 plasma virus populations.

Authors:  Katharina Skrabal; Virginie Trouplin; Béatrice Labrosse; Véronique Obry; Florence Damond; Allan J Hance; François Clavel; Fabrizio Mammano
Journal:  AIDS       Date:  2003-04-11       Impact factor: 4.177

8.  In vivo evolution of human immunodeficiency virus type 1 toward increased pathogenicity through CXCR4-mediated killing of uninfected CD4 T cells.

Authors:  Andreas Jekle; Oliver T Keppler; Erik De Clercq; Dominique Schols; Mark Weinstein; Mark A Goldsmith
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

9.  Identification of inflections in T-cell counts among HIV-1-infected individuals and relationship with progression to clinical AIDS.

Authors:  S J Gange; A Muñoz; J S Chmiel; A D Donnenberg; L M Kirstein; R Detels; J B Margolick
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

10.  CXCR4-mediated T cell apoptosis in human immunodeficiency virus infection.

Authors:  Anne-Zélie Decrion; Audrey Varin; Jean-Marie Estavoyer; Georges Herbein
Journal:  J Gen Virol       Date:  2004-06       Impact factor: 3.891

View more
  38 in total

1.  Low frequency of CXCR4-using viruses in patients at the time of primary non-subtype-B HIV-1 infection.

Authors:  Pierre Frange; Marie-Laure Chaix; Stéphanie Raymond; Julie Galimand; Christiane Deveau; Laurence Meyer; Cécile Goujard; Christine Rouzioux; Jacques Izopet
Journal:  J Clin Microbiol       Date:  2010-08-04       Impact factor: 5.948

2.  Mutational pathways and genetic barriers to CXCR4-mediated entry by human immunodeficiency virus type 1.

Authors:  Wei Huang; Arne Frantzell; Jonathan Toma; Signe Fransen; Jeannette M Whitcomb; Eric Stawiski; Christos J Petropoulos
Journal:  Virology       Date:  2010-11-10       Impact factor: 3.616

Review 3.  Newer antiretroviral agents and how to use them.

Authors:  Holly H Kim; Eric S Daar
Journal:  Curr HIV/AIDS Rep       Date:  2009-05       Impact factor: 5.071

4.  Newer antiretroviral agents and how to use them.

Authors:  Holly H Kim; Eric S Daar
Journal:  Curr Infect Dis Rep       Date:  2009-07       Impact factor: 3.725

5.  Detecting and understanding genetic and structural features in HIV-1 B subtype V3 underlying HIV-1 co-receptor usage.

Authors:  Mengjie Chen; Valentina Svicher; Anna Artese; Giosuè Costa; Claudia Alteri; Francesco Ortuso; Lucia Parrotta; Yang Liu; Chang Liu; Carlo Federico Perno; Stefano Alcaro; Jing Zhang
Journal:  Bioinformatics       Date:  2013-01-06       Impact factor: 6.937

6.  CD133+ hematopoietic progenitor cells harbor HIV genomes in a subset of optimally treated people with long-term viral suppression.

Authors:  Lucy A McNamara; Adewunmi Onafuwa-Nuga; Nadia T Sebastian; James Riddell; Dale Bixby; Kathleen L Collins
Journal:  J Infect Dis       Date:  2013-04-03       Impact factor: 5.226

7.  HIV-1 tropism testing and clinical management of CCR5 antagonists: Quebec review and recommendations.

Authors:  Cécile Tremblay; Isabelle Hardy; Richard Lalonde; Benoit Trottier; Irina Tsarevsky; Louis-Philippe Vézina; Michel Roger; Mark Wainberg; Jean-Guy Baril
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

8.  Pharmacokinetics and pharmacodynamics of TBR-652, a novel CCR5 antagonist, in HIV-1-infected, antiretroviral treatment-experienced, CCR5 antagonist-naïve patients.

Authors:  Jean-Francois Marier; MyMy Trinh; Leng Hong Pheng; Sandra M Palleja; David E Martin
Journal:  Antimicrob Agents Chemother       Date:  2011-04-12       Impact factor: 5.191

9.  Late-emerging strains of HIV induce T-cell homeostasis failure by promoting bystander cell death and immune exhaustion in naïve CD4 and all CD8 T-cells.

Authors:  Catherine N Kibirige; Frederick A Menendez; Hao Zhang; Tricia L Nilles; Susan Langan; Joseph B Margolick
Journal:  Med Hypotheses       Date:  2014-04-13       Impact factor: 1.538

10.  V3 loop sequence space analysis suggests different evolutionary patterns of CCR5- and CXCR4-tropic HIV.

Authors:  Katarzyna Bozek; Alexander Thielen; Saleta Sierra; Rolf Kaiser; Thomas Lengauer
Journal:  PLoS One       Date:  2009-10-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.